Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET | Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
HC2 Logo.jpg
HC2 Holdings Portfolio Company R2 Technologies Receives Final Tranche of $30 Million Investment
February 03, 2021 08:45 ET | HC2 Holdings, Inc.
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or “the Company”) (NYSE: HCHC) today announced that R2 Technologies Inc. ("R2"), founded by HC2’s portfolio company Pansend Life...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
September 28, 2020 09:00 ET | Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
AMR Logo.png
Pain Management Devices Market to Reach $6.77 Billion by 2026 at 6.7% CAGR
August 26, 2020 10:15 ET | Allied Market Research
Portland, OR, Aug. 26, 2020 (GLOBE NEWSWIRE) -- According to the report, the global pain management devices industry accounted for $4.01 billion in 2018, and is anticipated to reach $6.77 billion by...
Berg Nutrition Brings a Unique Form of Pure Capsaicin Called aXivite to U.S. Marketplace
July 28, 2020 10:02 ET | Berg Nutrition
ANN ARBOR, Mich., July 28, 2020 (GLOBE NEWSWIRE) -- Berg Nutrition has been named the exclusive U.S. distributer of the branded ingredient, aXivite phenylcapsaicin, a synthetic, innovative form of...
Biotricity Launches Innovative Pain Management Product with NeuPath Health
March 10, 2020 08:00 ET | biotricity
REDWOOD CITY, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has launched its...
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
January 27, 2020 07:00 ET | Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
Adynxx Reports Third Quarter 2019 Financial Results
November 14, 2019 06:00 ET | Adynxx, Inc.
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
October 28, 2019 07:57 ET | Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
October 15, 2019 08:46 ET | Aptinyx Inc.
EVANSTON, Ill., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...